Objectives: This study was aimed to evaluate the effects of the Breathworks' Mindfulness for Stress 8-week course on depressive and psychiatric symptoms, and on positive and negative affects, compared with active control and wait list. Method: A total of 84 primary care health professionals enrolled in the study, in quasi-experimental research design. The scales Beck Depression Inventory, Self-Reporting Questionnaire, Positive and Negative Affect Schedule, Self-Compassion Scale, and Five Facets of Mindfulness Questionnaire were applied before and after the interventions. Results: Depressive symptoms, psychiatric symptoms, and negative affects had a statistically significant decrease before postintervention evaluations in Mindfulness for Stress group, and the levels of self-compassion and observe and non-reactivity dimensions of mindfulness improved after the intervention. Conclusions: The Mindfulness for Stress program can be considered a feasible group intervention to improve the mental health of healthcare professionals.

No abstract

Objective Our aim was to explore the feasibility, and efficacy of a Dialectical Behavior Therapy Skill Training Group (DBT‐ST) as an add‐on treatment for adult attention‐deficit/hyperactivity disorder (ADHD) in Latin America. Method Adults with ADHD (n = 31) with stable medication treatment for ADHD and residual symptoms (ASRS > 20) were randomly assigned to DBT‐ST (n = 16) or treatment as usual (TaU; n = 15) for 12 weeks. Feasibility was accessed by attendance and completion rates at 12 weeks. Efficacy outcomes were measured with the ASRS, and performed at 0, 6, 12, and 16 weeks. Results The DBT‐ST protocol had 81.25% completion rate, with a mean attendance of 87.25% of the sessions. No significant interactions between group and time were detected for outcome measures. Discussion The DBT‐ST was feasible as add‐on treatment for adult patients with ADHD in Latin America. Replicating previous findings, DBT‐ST has shown no significantly higher improvement in ADHD symptoms in comparison with TaU. Registered at the Clinical Trials database (NCT03326427).